Brief: Mabion Terminates Deal With Parexel International For MabionCD20 Clinical Trial
22/05/2023 07:56
May 22 (Reuters) - Mabion SA MABP.WA :
* MANAGEMENT RESOLVES TO TERMINATE DEAL WITH PAREXEL
INTERNATIONAL
* DECISION OF COMPANY'S MANAGEMENT BOARD IS DICTATED BY
IMPLEMENTATION OF COMPANY'S STRATEGY FOR 2023-2027
* SAID DEAL WAS FOR MABIONCD20 CLINICAL TRIAL
Source text for Eikon: ID:nEMb75Gsza
Further company coverage: MABP.WA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Mabion SA
See all newsBrief: Mabion Partner Oddifact Says FDA Consultations Allow MabionCD20 To Be Used As First-Line Therapy For ITP
Brief: Mabion Holds Pre-IND Type B Meeting With FDA On MabionCD20 Development For ITP
Brief: Mabion Signs LoI With WPD Pharmaceuticals On Extension Of Cooperation
Brief: Mabion Q2 Net Loss At 15 Mln Zlotys
Brief: Mabion Signs Deal With Novavax Expanding Cooperation To Analytical Services For Early-Stage Pipeline Projects